Notable Upgrades: Amarin Corp. (AMRN), Wolverine World Wide (WWW), The Carlyle Group (CG), Eagle Pharmaceuticals (EGRX), Neuralstem (CUR)

In a report published Wednesday, Sun Trust Rbsn Humphrey analysts upgraded shares of Amarin Corporation (AMRN) to ‘Buy’ from ‘Neutral’. The move comes on solid volume too with the issue currently trading 3.4 million shares, compared to the average volume of 1.5 million shares.

On valuation measures, Amarin Corporation shares have a PEG ratio and T-12 price/sales of (0.03) and 4.31, respectively. EPS is ($0.53). AMRN has a median Wall Street price target of $2.00.

In the past 52 weeks, shares of Dublin, Ireland-based company have traded between a low of $0.78 and a high of $2.09 and are now up 13.47% to $1.33. Shares are down 32.57% year-over-year ; up 20.45% year-to-date.

Analysts at Sterne Agee upgraded their Wolverine World Wide Inc. (WWW) rating to ‘Neutral’ from ‘Underperform’ following the company’s fourth-quarter results on Tuesday. The Rockford, Michigan-based firm matched estimates with adjusted quarterly profit of $0.30 per share, while revenue of 808.9 million was above estimates of $808.1 million. However, Wolverine lowered its guidance for the year, saying it now expects 2015 EPS in the range of $1.53 – $1.60 per share, with revs in the range of $2.82 billion – $2.87 billion.

WWW shares recently gained $1.35 to $29.58. In the past 52 weeks, shares of the footwear maker have traded between a low of $24.00 and a high of $30.75. Shares are up 1.62% year-over-year ; down 4.21% year-to-date.

Analysts at Citigroup (C) upgraded shares of The Carlyle Group LP (CG) to ‘Buy’ from ‘Neutral’ in a research report issued to clients this morning.

On valuation measures, CG shares are currently priced at 23.21x this year’s forecasted earnings, compared to the industry’s 22.30x earnings multiple. The company’s current year and next year EPS growth estimates stand at (1.50%) and 12.10% compared to the industry growth rates of 3.30% and 23.60%, respectively. CG has a t-12 price/sales ratio of 0.49. EPS for the same period registers at $1.23.

CG’s shares have advanced 12.89% in the last 4 weeks and declined 5.62% in the past three months. Over the past 5 trading sessions the stock has gained 4.01%. Shares of The Carlyle Group LP are up 1.89% this year.

The Palo Alto-based company, which is currently valued at $1.93B, has a median Wall Street price target of $32.00 with a high target of $38.00.

Brean Capital initiated coverage on Neuralstem, Inc. (CUR) with a ‘Buy’ and price target of $8.00, implying 107% expected return.

Neuralstem shares recently gained $0.32 to $3.86. The name is up more than 5.99% year-over-year and has gained roughly 30.15% year-to-date. In the past 52 weeks, shares of Rockville, Maryland-based biopharmaceutical company have traded between a low of $2.12 and a high of $4.81.

Neuralstem, Inc. closed Tuesday at $3.54. The name has a total market cap of $336.77M.

Shares Eagle Pharmaceuticals Inc. (EGRX) are up $6.34, or 24.29%, at $32.44, after Cantor Fitzgerald initiated coverage of the stock with a ‘Buy’ rating and a $37 from $30 price target. Approximately 1.2M shares have already changed hands, compared to the stock’s average daily volume of 99K shares.

Eagle Pharmaceuticals Inc. on Tuesday reported a loss of $5.5 million in its Q4’14. On a per-share basis, the specialty pharmaceutical based-company said it had a loss of $0.39 per share.

For the year, Eagle Pharma reported that its loss narrowed to $18 million, or $1.97 per share.

Shares of EGRX are up 150% year-over-year, and 109% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*